alexa Journal of Oncology Translational Research
ISSN: 2476-2261

Journal of Oncology Translational Research
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

Editorial Board

Recommended Conferences

  • Global Experts meeting on Oncology Case Reports
    Aug 29-31, 2017 London, UK
  • 25th World Congress on Cancer Science and Therapy
    October 18-20, 2017 Baltimore, Maryland, USA
  • 25th World Cancer Conference
    Oct 19-21, 2017 Rome, Italy

About the Journal

Oncology Translational Research is an International journal devoted to fostering research investigations which bridge the laboratory and clinical settings. It covers all aspects of research on cancer, from the more basic discoveries dealing with both cell and molecular biology of tumour cells, to the most advanced clinical assays of conventional and new drugs including risk assessment, cellular and molecular characterization, prevention, detection, diagnosis and treatment of human cancers with the overall goal of improving the clinical care of oncology patients. In addition, the journal has a strong commitment to facilitating the transfer of knowledge from the basic laboratory to the clinical practice, with the publication of educational series devoted to closing the gap between molecular and clinical oncologists. A broad spectrum of subjects, including the molecular and cellular bases of disease, aetiology, pathophysiology, pathology, epidemiology, clinical features, and the diagnosis, prognosis and treatment of cancer, will be considered for publication.

Translational Oncology will publish laboratory studies of novel therapeutic interventions as well as clinical trials which evaluate new treatment paradigms for cancer. Case reports describing unusual clinical cases or examples of unique reports dedicated to translational research will also be within the scope of the journal.

The Journal of Oncology Translational research is a Open Access Scientific Journal that offers an interesting publishing platform globally and aims to keep scientists, clinicians and medical practitioners, researchers, and students informed and updated on the ongoing research in the relevant area. Outstanding quality articles are welcome to maintain the highest standard of the journal and to achieve high impact factor.

Journal of Oncology Translational research is using Editorial tracking System for maintaining the quality in peer review process. Editorial tracking is an online manuscript submission, review and tracking system. Review processing is performed by the editorial board members of Journal of Oncology Translational research or by outside experts. At least two independent reviewers approval followed by editor approval is required for acceptance of any citable manuscript. Authors may submit manuscripts and track their progress through the system, hopefully to publication. Reviewers can download manuscripts and submit their opinions to the editor. Editors can manage the whole submission/review/revise/publish process.

Genetics and Epigenetics

“Epigenetics” refers to covalent modification of DNA, protein, or RNA, resulting in changes to the function and/or regulation of these molecules, without altering their primary sequences. Genetics & Epigenetics topics include bookmarking, DNA methylation, gene silencing, histone modification, genomic imprinting, maternal effects, paramutation, the position effect, reprogramming, transvection, and X chromosome inactivation. All aspects of the study of these phenomena are of interest, including technical and ethical issues.

Antiangiogenic Therapies

A monoclonal antibody targeting vascular endothelial growth factor, was approved as antiangiogenic therapy. Antiangiogenesis therapy is one of two types of drugs in a new class of medicines that restores health by controlling blood vessel growth.The other medication is called pro-angiogenic therapy. Antiangiogenic therapy inhibits the growth of new blood vessels. Because new blood vessel growth plays a critical role in many disease conditions, including disorders that cause blindness, arthritis, and cancer.

Programmed Cell Death

Programmed cell-death (or PCD) is death of a cell in any form, mediated by an intracellular program. PCD is carried out in a regulated process, which usually confers advantage during an organism's life-cycle.

Cancer Epigenome

Cancer epigenetics is the study of epigenetic modifications to the genome of cancer cells that do not involve a change in the nucleotide sequence. Epigenetic alterations are as important as genetic mutations in a cell’s transformation to cancer.

Cancer Risk

The likelihood of developing malignancy, which is the combined result of lifestyle and genetics. Risk estimates for cancer and other diseases are determined by studying large groups of people. Absolute risk refers to the actual numeric chance or probability of developing cancer during a specified time period.

Genetic instability

Genetic instability refers to a high frequency of mutations within the genome of a cellular lineage. These mutations can include changes in nucleic acid sequences, chromosomal rearrangements or aneuploidy. It is a major driving force for tumorigenesis.

Vaccine Strategies

Vaccines are one of the most effective methods of controlling infectious disease. Although vaccination has been used for centuries, the technologies are largely empirical with little understanding of the underlying immunological principles and physiological mechanisms. In general, a vaccine strategy is composed of a method to deliver target antigens or epitopes to the immune system and an immune-stimulating adjuvant to trigger an immune response.

Clinical Cancer

Clinical Cancer is the field of medicine that is devoted to cancer. Clinical cancer consists of three primary disciplines: medical oncology, surgical oncology and radiation oncology. A biopsy often is needed to confirm a cancer diagnosis. Biopsies might also be needed to find out if an abnormal spot seen on an imaging test is really cancer spread. During a biopsy, the doctor removes a tumor or pieces of a tumor to be looked at under a microscope.

Tumor Associated Inflammation

The tumor microenvironment is often infiltrated by innate and adaptive immune system cells that enable tumors to mimic inflammatory conditions seen in normal tissues. Current molecular cancer research indicates that this tumor-associated inflammation might aid in tumor growth. Inflammatory conditions in selected organs increase the risk of cancer. An inflammatory component is present also in the microenvironment of tumors that are not epidemiologically related to inflammation

Carcinomas

Carcinomas are cancers or malignancies which are begin in the epithelial tissues. Carcinomas may affect any part of the body and are among the most common types of cancer in adults. Carcinoma spreads by metastasis and often recurs after excision. Carcinomas are classified as adrenocortical carcinomas thyroid carcinomas nasopharyngeal carcinomas malignant melanoma and skin carcinoma.


Recently Published Articles

Triple Negative Breast Cancer: Its Time to Kick the Can down the Road
Sandra S Hatch
 
Duodenal Stump Leak Post Curative Gastrectomy for Early Gastric Cancer Patient Treated With Endoscopic Stent which Complicated by Migration and Perforation
Bandar Ali, Jin Won Lee and Kyo Young Song
 
Once Daily High-dose Radiation (≥60 Gy) Treatment in Limited Stage Small Cell Lung Cancer
Amir Zahra DO, Tangel Chang DO, Taher Abu Hejleh, Muhammad Furqan, Gerald H Clamon, Sudershan K Bhatia, John M Watkins, Sarah L Mott MS, Douglas R Spitz, John M Buatti and Bryan G Allen
 
In Ovo Progression of Borderline Ovarian Tumors
Meynier S, Undurraga M, Tille JC, Petignat P and Cohen M
 
When is Good, Good Enough? Methodological Pragmatism for Sustainable Guideline Development: Democratization of Processes for Setting Methodological Standards for Trustworthy Clinical Practice Guidelines
George P Browman and Melissa C Brouwers
 
Fatal Gestational Trophoblastic Neoplasia
John R Lurain
 
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords